| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 11 | 2024 | 632 | 1.860 |
Why?
|
| Influenza Vaccines | 8 | 2024 | 458 | 1.630 |
Why?
|
| Hospitalization | 23 | 2024 | 1717 | 1.360 |
Why?
|
| Intubation, Intratracheal | 9 | 2024 | 284 | 1.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2024 | 175 | 0.950 |
Why?
|
| Critical Illness | 8 | 2024 | 587 | 0.860 |
Why?
|
| Laryngoscopes | 4 | 2023 | 68 | 0.780 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2019 | 4 | 0.680 |
Why?
|
| Bronchoscopy | 5 | 2019 | 153 | 0.670 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 21 | 0.670 |
Why?
|
| Pneumonia | 2 | 2022 | 326 | 0.650 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 36 | 0.640 |
Why?
|
| Vaccination | 9 | 2024 | 881 | 0.630 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 191 | 0.570 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 448 | 0.560 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 328 | 0.520 |
Why?
|
| Pleurisy | 1 | 2015 | 6 | 0.520 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 3 | 0.510 |
Why?
|
| Time | 1 | 2015 | 90 | 0.500 |
Why?
|
| Risk Assessment | 3 | 2015 | 3200 | 0.500 |
Why?
|
| Adult | 39 | 2024 | 28363 | 0.490 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 29 | 0.480 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 41 | 0.470 |
Why?
|
| Humans | 71 | 2024 | 121045 | 0.450 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 164 | 0.450 |
Why?
|
| Aged | 29 | 2024 | 18399 | 0.440 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2019 | 191 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 1977 | 0.430 |
Why?
|
| Laryngoscopy | 3 | 2023 | 147 | 0.430 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2012 | 7 | 0.420 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 220 | 0.400 |
Why?
|
| Middle Aged | 29 | 2024 | 25263 | 0.390 |
Why?
|
| Hypoxia | 2 | 2024 | 247 | 0.380 |
Why?
|
| Pneumonectomy | 1 | 2012 | 140 | 0.370 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 457 | 0.370 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 2779 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 200 | 0.370 |
Why?
|
| Heart Arrest | 3 | 2024 | 342 | 0.370 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2019 | 71 | 0.360 |
Why?
|
| Shock | 2 | 2022 | 89 | 0.360 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 31 | 0.350 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 550 | 0.340 |
Why?
|
| United States | 17 | 2024 | 10332 | 0.310 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 298 | 0.310 |
Why?
|
| Female | 33 | 2024 | 63993 | 0.310 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 113 | 0.290 |
Why?
|
| Case-Control Studies | 7 | 2024 | 3209 | 0.290 |
Why?
|
| Seasons | 3 | 2024 | 292 | 0.270 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 156 | 0.260 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 6 | 0.260 |
Why?
|
| Male | 26 | 2024 | 58908 | 0.260 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1870 | 0.250 |
Why?
|
| Bias | 1 | 2024 | 107 | 0.230 |
Why?
|
| Polysomnography | 3 | 2019 | 132 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 88 | 0.220 |
Why?
|
| Influenza A virus | 1 | 2024 | 134 | 0.220 |
Why?
|
| Hemoptysis | 2 | 2021 | 21 | 0.220 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 117 | 0.210 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2826 | 0.200 |
Why?
|
| Respiratory Paralysis | 1 | 2001 | 7 | 0.200 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 8 | 0.200 |
Why?
|
| Pulmonary Atelectasis | 1 | 2001 | 14 | 0.200 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 230 | 0.200 |
Why?
|
| Fluid Therapy | 1 | 2022 | 121 | 0.190 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 95 | 0.190 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 41 | 0.190 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 263 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6091 | 0.180 |
Why?
|
| Hypotension | 1 | 2022 | 175 | 0.180 |
Why?
|
| Aneurysm | 1 | 2021 | 73 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 122 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2024 | 308 | 0.180 |
Why?
|
| Adolescent | 9 | 2024 | 18730 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 260 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2022 | 163 | 0.180 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2019 | 3 | 0.170 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 74 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 2021 | 97 | 0.170 |
Why?
|
| Intensive Care Units | 3 | 2024 | 474 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 48 | 0.170 |
Why?
|
| Mediastinitis | 2 | 2017 | 13 | 0.170 |
Why?
|
| Azithromycin | 1 | 2019 | 45 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2021 | 348 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 111 | 0.160 |
Why?
|
| Cough | 1 | 2019 | 87 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2002 | 378 | 0.160 |
Why?
|
| Fatal Outcome | 1 | 2019 | 348 | 0.150 |
Why?
|
| Home Care Services | 1 | 2018 | 65 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2024 | 5854 | 0.150 |
Why?
|
| Hospital Mortality | 4 | 2024 | 976 | 0.150 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 23 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 203 | 0.140 |
Why?
|
| Long-Term Care | 1 | 2017 | 72 | 0.140 |
Why?
|
| Fever | 1 | 2019 | 291 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 44 | 0.140 |
Why?
|
| Young Adult | 7 | 2024 | 8627 | 0.140 |
Why?
|
| CA-125 Antigen | 1 | 1996 | 12 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2017 | 98 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 594 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 837 | 0.130 |
Why?
|
| Bacteremia | 1 | 2020 | 406 | 0.130 |
Why?
|
| Abdominal Neoplasms | 1 | 1996 | 33 | 0.130 |
Why?
|
| Oxygen | 3 | 2024 | 537 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1284 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 154 | 0.130 |
Why?
|
| Carmine | 1 | 1995 | 1 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2370 | 0.130 |
Why?
|
| Parasitic Diseases | 1 | 1996 | 57 | 0.130 |
Why?
|
| Leiomyoma | 1 | 1996 | 90 | 0.130 |
Why?
|
| Vulvar Neoplasms | 1 | 1995 | 17 | 0.120 |
Why?
|
| Logistic Models | 2 | 2021 | 1741 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 38 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 75 | 0.120 |
Why?
|
| Legionella | 1 | 2014 | 8 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 240 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 227 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1023 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2017 | 367 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 146 | 0.110 |
Why?
|
| Lung | 3 | 2014 | 1461 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 37 | 0.110 |
Why?
|
| Algorithms | 1 | 2019 | 1568 | 0.100 |
Why?
|
| Influenza B virus | 2 | 2024 | 86 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1612 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 1215 | 0.100 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1049 | 0.100 |
Why?
|
| Video Recording | 2 | 2023 | 180 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2020 | 15563 | 0.100 |
Why?
|
| Trachea | 2 | 2023 | 189 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 512 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 4472 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 259 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2055 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1583 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2123 | 0.090 |
Why?
|
| RNA | 2 | 2023 | 577 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2024 | 4577 | 0.080 |
Why?
|
| Biopsy | 1 | 2012 | 1238 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2017 | 1152 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 4957 | 0.070 |
Why?
|
| Sleep | 2 | 2019 | 335 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 18 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 422 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2023 | 688 | 0.060 |
Why?
|
| Masks | 1 | 2024 | 36 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2004 | 85 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 181 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 62 | 0.060 |
Why?
|
| Vincristine | 1 | 2004 | 207 | 0.060 |
Why?
|
| Bronchial Diseases | 1 | 2003 | 10 | 0.060 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 140 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 5975 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 5 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 306 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 12 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1223 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 83 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2001 | 4 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 32 | 0.050 |
Why?
|
| Sarcoma | 1 | 2004 | 197 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 97 | 0.050 |
Why?
|
| Heart Septum | 1 | 2001 | 57 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 293 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 372 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 138 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 392 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 135 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 525 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 236 | 0.050 |
Why?
|
| Diaphragm | 1 | 2001 | 97 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 20 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3508 | 0.050 |
Why?
|
| Subclavian Artery | 1 | 2021 | 65 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 208 | 0.050 |
Why?
|
| Prevalence | 2 | 2023 | 2346 | 0.050 |
Why?
|
| Enterococcus | 1 | 2020 | 33 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 151 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 240 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 202 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 739 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 485 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 36 | 0.040 |
Why?
|
| Heart Atria | 1 | 2001 | 308 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2003 | 314 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2017 | 11680 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 216 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1542 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 489 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1086 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1144 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 230 | 0.040 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 30 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 630 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1243 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 6 | 0.040 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 5 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 384 | 0.040 |
Why?
|
| Fallopian Tube Diseases | 1 | 1997 | 12 | 0.040 |
Why?
|
| Length of Stay | 2 | 2017 | 1258 | 0.040 |
Why?
|
| Ileal Diseases | 1 | 1997 | 20 | 0.040 |
Why?
|
| Intestinal Fistula | 1 | 1997 | 29 | 0.030 |
Why?
|
| Stents | 2 | 2017 | 684 | 0.030 |
Why?
|
| Critical Care | 1 | 2002 | 644 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.030 |
Why?
|
| Fistula | 1 | 1997 | 50 | 0.030 |
Why?
|
| Risk Factors | 3 | 2024 | 9603 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 164 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 597 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 250 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1968 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1092 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 20 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1037 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 2965 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 73 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 371 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1396 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 721 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 28 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 306 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 46 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 266 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 187 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 485 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 99 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 33472 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1352 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2787 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 505 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2003 | 2869 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 1709 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 1003 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2004 | 1454 | 0.020 |
Why?
|
| Ohio | 1 | 2006 | 86 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2006 | 24 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 193 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 260 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2006 | 290 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2006 | 194 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 370 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 51 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 267 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 158 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 398 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1230 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 642 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1240 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1389 | 0.010 |
Why?
|
| Adnexal Diseases | 1 | 1997 | 22 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2001 | 1107 | 0.010 |
Why?
|